E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B
Author(s) -
David Engelmann,
Deborah Mayoli-Nüssle,
Christian Mayrhofer,
Katharina Fürst,
Vijay Alla,
Anja Stoll,
Alf Spitschak,
Kerstin Abshagen,
Brigitte Vollmar,
Sophia Ran,
Brigitte M. Pützer
Publication year - 2013
Publication title -
journal of molecular cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.825
H-Index - 62
eISSN - 1674-2788
pISSN - 1759-4685
DOI - 10.1093/jmcb/mjt035
Subject(s) - angiogenesis , cancer research , downregulation and upregulation , e2f1 , biology , platelet derived growth factor receptor , gene knockdown , microbiology and biotechnology , vascular endothelial growth factor , neovascularization , growth factor , vascular endothelial growth factor a , receptor , cancer , cell cycle , cell culture , vegf receptors , genetics , gene
Angiogenesis is essential for primary tumor growth and metastatic dissemination. E2F1, frequently upregulated in advanced cancers, was recently shown to drive malignant progression. In an attempt to decipher the molecular events underlying this behavior, we demonstrate that the tumor cell-associated vascular endothelial growth factor-C/receptor-3 (VEGF-C/VEGFR-3) axis is controlled by E2F1. Activation or forced expression of E2F1 in cancer cells leads to the upregulation of VEGFR-3 and its ligand VEGF-C, whereas E2F1 depletion prevents their expression. E2F1-dependent receptor induction is crucial for tumor cells to enhance formation of capillary tubes and neovascularization in mice. We further provide evidence for a positive feedback loop between E2F1 and VEGFR-3 signaling to stimulate pro-angiogenic platelet-derived growth factor B (PDGF-B). E2F1 or VEGFR-3 knockdown results in reduced PDGF-B levels, while the coexpression synergistically upregulates promoter activity and endogenous protein expression of PDGF-B. Our findings delineate an as yet unrecognized function of E2F1 as enhancer of angiogenesis via regulation of VEGF-C/VEGFR-3 signaling in tumors to cooperatively activate PDGF-B expression. Targeting this pathway might be reasonable to complement standard anti-angiogenic treatment of cancers with deregulated E2F1.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom